Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Nicola Westgate's Articles

Female Innovation Exhibition features OBN Member Fiona Marston, CEO of Absynth Biologics Limited

For the full news article, please see http://www.bbc.co.uk/news/in-pictures-40582699 

Precision for Medicine Expands Its Global Footprint for Oncology Development Services

Leadership in place; Clinical Operations teams growing throughout Europe

BETHESDA, Md., July 6, 2017 /PRNewswire/ -- Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.

Exscientia enters strategic drug discovery collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.

BeamLine Diagnostics’ closes a £650k investment round

Beamline Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) and other investors.

Exscientia Announces €250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease. Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s powerful bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets. Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pa ...

Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.

Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.  Published quarterly, this newsletter will aim to cover key topics in the biopharmaceutical industry. CREDOS is a specialist consultancy tailored to the discovery and development of biological therapeutics (www.credos-bio.co.uk)

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.